Personalized mRNA cancer vaccine reportedly cuts melanoma death and recurrence by 42%

Ars Technica, via a Mastodon post, reports that Moderna and Merck released top-line trial results showing a personalized mRNA cancer vaccine cut melanoma death or recurrence by 42%. Only one item was collected, so the claim is not yet independently cross-checked.

Timeline

1. 23 Oct, 04:27 UTCFirst appeared on The Guardian

Top sources

• ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial showsThe Guardian